A phase I study of hepatic arterial infusion using difluoromethylornithine.
作者信息
Lipton A, Harvey H A, Glenn J, Weidner W A, Strauss M, Miller S E, Taylor J B, White-Hershey D, Barlow J L
机构信息
Division of Oncology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
出版信息
Cancer. 1989 Feb 1;63(3):433-7. doi: 10.1002/1097-0142(19890201)63:3<433::aid-cncr2820630306>3.0.co;2-5.
Abstract
Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.
摘要
Zotero 插件